Compare Crispr Therapeutics AG (CRSP) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Toyota Motor Corp — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Toyota Motor Corp trades at $185.3 (market cap $217.38B). The key difference: Toyota Motor Corp is far larger — about 44.5× Crispr Therapeutics AG's market cap, and Toyota Motor Corp pays a 3.37% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Toyota Motor Corp for 116 Days on average.
| CRSP | TM | |
|---|---|---|
Market Cap | $4.88B | $217.38B |
Volume | 2,861,747 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $73.97 | $248.29 |
52-Week Low | $44.34 | $166.50 |
Typical Hold Time | 77 Days | 116 Days |
Enterprise Value | $3.30B | $410.96B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Toyota Motor (TM) trades at $186.00, up 1.69% today, with a bearish technical signal but strong fundamentals. The stock shows attractive valuation ratios, including a P/E of 8.38 and P/B of 0.93, and has beaten EPS estimates in recent quarters. Recent news highlights U.S. sales growth and electrification efforts, though production declines in China and floods in Thailand pose challenges. Cash flow turned negative in 2025 but is projected to rebound in 2026.
TM presents a value opportunity with low multiples and consistent profitability, but near-term headwinds from global sales softness and supply chain disruptions warrant caution. Analyst consensus is mixed, with 37.5% buy ratings versus 62.5% hold, reflecting balanced optimism and patience. The stock's outlook hinges on execution in electrification and recovery in key markets like China.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
